Article
Immunology
Alba Rodriguez-Garcia, Maria Linares, Maria Luz Morales, Sophie Allain-Maillet, Nicolas Mennesson, Ricardo Sanchez, Rafael Alonso, Alejandra Leivas, Alfredo Perez-Rivilla, Edith Bigot-Corbel, Sylvie Hermouet, Joaquin Martinez-Lopez
Summary: This study reports on the association between HCV infection and the progression of MGUS and MM. The results suggest a causal relationship and show that antiviral treatment can lead to better disease progression. When HCV is eliminated, clonal plasma cells can be controlled, providing new possibilities for the treatment of MGUS and myeloma.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
David L. Wyles, Minhee Kang, Roy M. Matining, Robert L. Murphy, Marion G. Peters
Summary: The final results of the long-term Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) indicate low rates of HCV recurrence after direct-acting antiviral therapy in both HCV/HIV-coinfected and HCV-infected groups with over 500 person-years of follow-up. Confirmed reinfections were primarily reported in participants with HIV who engaged in high-risk behaviors.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Review
Chemistry, Analytical
Vigneswaran Narayanamurthy, Z. E. Jeroish, K. S. Bhuvaneshwari, Fahmi Samsuri
Summary: Proper diagnosis is essential in avoiding disease consequences, especially for severe issues like hepatitis C virus (HCV) that can cause significant damage to the liver. Developing strategies for appropriate selection of POCT for HCV detection, initiating proper antiviral therapy, and defining associated risks is critical for achieving optimal outcomes. Alternative strategies are needed to enhance HCV diagnosis, with molecular assays being precise but requiring additional approaches for infected populations to improve detection.
ANALYTICAL METHODS
(2021)
Article
Gastroenterology & Hepatology
Vanessa Koo, Feng Tian, William W. L. Wong
Summary: HCV point-of-care testing is cost-effective for injection drug users, as it can prolong individuals' lifespan and save healthcare costs associated with HCV-related complications.
LIVER INTERNATIONAL
(2022)
Article
Immunology
Pierre Cappy, Quentin Lucas, Nakourogou Kankarafou, Camille Sureau, Syria Laperche
Summary: Following a study demonstrating the role of hepatitis C virus (HCV) in transmitting hepatitis D virus (HDV) in a liver-humanized mouse model, a large cohort of HCV-positive blood donors were screened for HDV markers. However, no evidence of HCV-assisted propagation of HDV in humans was found.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Ana Carrero, Juan Berenguer, Victor Hontanon, Josep M. Guardiola, Jordi Navarro, Miguel A. von Wichmann, Maria J. Tellez, Carmen Quereda, Ignacio Santos, Jose Sanz, Maria J. Galindo, Jose Hernandez-Quero, Maria A. Jimenez-Sousa, Leire Perez-Latorre, Jose M. Bellon, Salvador Resino, Herminia Esteban, Esteban Martinez, Juan Gonzalez-Garcia
Summary: Eradication of HCV did not lead to significant changes in BMD or biomarkers of bone remodeling in HIV/HCV-coinfected individuals.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Ben L. Da
Summary: Chronic hepatitis D infection lacks effective treatment options, but multiple investigational therapies are being evaluated. There is significant variability in the endpoints used to evaluate these therapies, and the optimal way to measure success in clinical trials remains unknown and will continue to evolve.
Article
Pharmacology & Pharmacy
Leandro Francisco Pippa, Carolina Pinto Vieira, Juciene Aparecida Caris, Adriana Rocha, Camile Prates Garcia, Rosamar Eulira Fontes Rezende, Vera Lucia Lanchote
Summary: This study assessed the effect of chronic hepatitis C on CYP2C19 activity and found that the metabolic ratios of patients in groups 1 and 2 changed after treatment with direct-acting antivirals, indicating partial reversal of CYP2C19 inhibition during inflammation.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Gastroenterology & Hepatology
Chun-Jen Liu, Pei-Jer Chen
Summary: Transmission of HBV and HCV is similar, leading to dual HBV/HCV infection in populations at risk. With universal childhood HBV vaccination and public education programs, the epidemiology of HBV and HCV infections is changing. Introduction of anti-HBV agents and direct acting antivirals for HCV will further impact the prevalence of dual HBV/HCV infection worldwide.
LIVER INTERNATIONAL
(2022)
Article
Public, Environmental & Occupational Health
Czarina N. Behrends, Sarah Gutkind, Regan Deming, Kyle R. Fluegge, Marie P. Bresnahan, Bruce R. Schackman
Summary: The removal of restrictions on HCV treatment by New York State FFS Medicaid was associated with some changes in Medicaid MCO PA decisions, but MCO PA denials and treatment delays were still observed on the ground by clinic staff.
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
(2021)
Review
Oncology
Yutaka Tsutsumi, Shinichi Ito, Souichi Shiratori, Takanori Teshima
Summary: The hepatitis C virus (HCV) can lead to liver cancer and is associated with lymphoma. Advances in drug treatment have improved outcomes, with the potential for HCV eradication using direct acting antivirals (DAA). HCV reactivation during lymphoma treatment and the role of HCV-RNA as a biomarker are also explored in this review.
Review
Infectious Diseases
Salima Davlidova, Zoe Haley-Johnson, Kate Nyhan, Ayesha Farooq, Sten H. Vermund, Syed Ali
Summary: In Central Asia and the Caucasus, the prevalence of HIV, HCV, and HBV remains exceedingly high among selected populations, notably among people who inject drugs (PWID) and men who have sex with men (MSM).
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biochemical Research Methods
Tinghua Li, Hongwei Zhang, Zhonggang Fang, Jun Yin, Wei Rao
Summary: The MAGLUMI Anti-HCV (CLIA) test showed high specificity (99.75% - 100.00%) and sensitivity (100.00%) in detecting HCV antibodies, making it suitable for HCV infection diagnosis.
JOURNAL OF VIROLOGICAL METHODS
(2023)
Article
Computer Science, Interdisciplinary Applications
Fabio Polisano, Andrea Dan Ryals, Gabriele Pannocchia, Alberto Landi
Summary: This study proposes a strategy to optimize hepatitis C treatment using model predictive control, which successfully reduces treatment costs while maintaining good pharmacological control. The results demonstrate the feasibility and effectiveness of this approach.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
(2021)
Article
Medicine, Research & Experimental
Mahmoud A. Khattab, Yehia Zakaria, Eslam Sadek, Aliaa S. Abd El Fatah, Magdy Fouad, Muhammed Khattab, Hend M. Moness, Nashwa Mohamed Adel, Elham Ahmed
Summary: The aim of this study was to investigate the persistence of HCV RNA in PBMCs after achieving SVR following DAA treatment. The study found that HCV RNA could still be detected in the PBMCs of 20% of HCV genotype 4 patients who achieved SVR, although the viral load was low. Higher posttreatment levels of AST and liver cirrhosis were identified as significant risk factors for the persistence of HCV infection in PBMCs.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Letter
Gastroenterology & Hepatology
Tai-Chung Tseng, Tetsuya Hosaka, Jia-Horng Kao
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Grishma Hirode, Bettina E. Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Wong, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sylvia M. Brakenhoff, Sabela Lens, Hannah S. J. Choi, Rong-Nan Chien, Jordan J. Feld, Xavier Forns, Milan J. Sonneveld, George V. Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Henry L. Y. Chan, Jia-Horng Kao, Yao-Chun Hsu, Markus Cornberg, Wen-Juei Jeng, Harry L. A. Janssen
Summary: Despite improvements in the management of chronic hepatitis B, the risk of cirrhosis and hepatocellular carcinoma remains. The rate of hepatic decompensation is low after discontinuation of nucleos(t)ide analog therapy, but higher in patients with cirrhosis and those who were HBeAg positive at the start of therapy.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Chian-Tzu Huang, Yu-Long Chu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) -A/B HCC beyond the Milan criteria with survival benefit. The study found that patients with tumor burden beyond the up-to-7 criteria but within 3 tumors had better overall survival (OS) with SR compared to transarterial chemoembolization (TACE), suggesting that SR should be considered in resectable patients.
Editorial Material
Medicine, General & Internal
Jia-Horng Kao
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Editorial Material
Medicine, General & Internal
Jia-Horng Kao
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, Research & Experimental
Li-Teh Liu, Jih-Jin Tsai, Justin Jang Hann Chu, Chun-Hong Chen, Liang-Jen Chen, Ping-Chang Lin, Ching-Yi Tsai, Miao-Chen Hsu, Wan-Long Chuang, Shang-Jyh Hwang, Inn-Wen Chong
Summary: In Taiwan, the COVID-19 outbreak involving the Delta variant followed the alpha variant in 2021. By analyzing Delta variant cases, it was found that the case fatality rate in Taiwan for Delta variants (0.94%) was lower compared to alpha variants (5.95%). This may be attributed to hybrid immunity from previous infection and the rapid COVID-19 vaccination program. The study identified specific gene deletions in the Delta variant that potentially affect viral pathogenesis and highlighted the potential threat of Delta-Omicron hybrid variants (deltacron) to public health.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
(2023)
Review
Gastroenterology & Hepatology
Chih-Lin Lin, Jia-Horng Kao
Summary: Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas. Hepatitis B viral load is the most important risk factor for HCC development. Antiviral therapy can reduce the risk of HCC occurrence and serum markers can predict the risk of HCC development.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Oncology
Zu-Yau Lin, Ming-Lun Yeh, Po-Cheng Liang, Po-Yao Hsu, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang
Summary: This study aimed to investigate the dose-dependent anti-cancer effect of lenvatinib on hepatocellular carcinoma (HCC) cells and the potential benefit of combined colchicine therapy. The results showed that lenvatinib did not exhibit a dose-dependent anti-cancer effect on HCC, but combined treatment with colchicine and lenvatinib promoted the overall anti-cancer effects on HCC.
Article
Gastroenterology & Hepatology
Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Summary: The new name and diagnostic criteria of metabolic-associated fatty liver disease (MAFLD) were proposed in 2020. The impact of chronic HBV infection on clinical outcomes of MAFLD was investigated using a Taiwan bio-bank cohort. The study revealed that chronic HBV infection increases the overall risk of liver fibrosis, but protects from atherosclerosis in patients with MAFLD.
Meeting Abstract
Gastroenterology & Hepatology
Edo Dongelmans, Grishma Hirode, Bettina Hansen, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Arno Furquim d'Almeida, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace Wong, Sylvia Brakenhoff, Rong-Nan Chien, Jordan J. Feld, Henry Ly Chan, Xavier Forns, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun (Holden) Hsu, Jia-Horng Kao, Markus Cornberg, Milan Sonneveld, Rachel Wen-Juei Jeng, Harry L. A. Janssen
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Tom Evans, Eleanor Barnes, Reena Mehta, Louise Bussey, Katie Anderson, Antonella Vardeu, Anthony Brown, Young-Suk Lim, Wan-Long Chuang, Chiyi Chen, Won Young Tak, Gin-Ho Lo
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Grishma Hirode, Bettina Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Wong, Wai-Kay Seto, Arno Furquim d'Almeida, Margarita Papatheodoridi, Sylvia Brakenhoff, Sabela Lens, Hannah S. J. Choi, Stijn Van Hees, Rong-Nan Chien, Jordan J. Feld, Xavier Forns, Milan Sonneveld, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Henry L. Y. Chan, Jia-Horng Kao, Yao-Chun (Holden) Hsu, Markus Cornberg, Rachel Wen-Juei Jeng, Harry L. A. Janssen
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Sih-Ren Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Shengshun Yang, Chia-Chi Wang, Jui-Ting Hu, Lien-Juei Mou, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Jia-Sheng Huang, Guei-Ying Chen, Jian-Neng Gao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Chiyi Chen, Kuo-Chih Tseng, Ming-Lung Yu
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chun-Jen Liu, Tung-Hung Su, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao
Summary: This study analyzed the patient characteristics and clinical performance of retreatment with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C virus (HCV) reinfection after viral clearance. The risk of reinfection was higher in HIV-positive patients than HIV-negative patients. Treating reinfected patients with pangenotypic DAAs showed excellent effectiveness and tolerance, regardless of prior DAA exposure or viral genotypes/subtypes.
ADVANCES IN DIGESTIVE MEDICINE
(2023)